Elanco Animal Health (ELAN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $13.39B
Last updated: Nov 17, 2026 at 11:05 AM ET
Elanco Animal Health (ELAN) Earnings: Report Dates and Results
Elanco Animal Health (ELAN) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Elanco Animal Health reported EPS of $0.27, above the $0.20 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ELAN has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 38.5% above the $0.13 reported for the quarter ended Dec 31, 2025.
ELAN Earnings Call
The latest ELAN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 33 quarters below that had an estimate, ELAN beat 29, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.26B, up 10.5% from $1.14B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.27 | $0.20 | $0.19 - $0.21 | +35.00% | Beat | +42.1% | 12 | 1 up, 0 down | Nov 6, 2026 | $1.26B |
| Jun 30, 2026 | $0.34 | $0.27 | $0.26 - $0.29 | +25.93% | Beat | +30.8% | 12 | 1 up, 1 down | Aug 5, 2026 | $1.37B |
| Mar 31, 2026 | $0.40 | $0.34 | $0.33 - $0.35 | +17.65% | Beat | +8.1% | 12 | 0 up, 3 down | May 6, 2026 | $1.37B |
| Dec 31, 2025 | $0.13 | $0.11 | $0.10 - $0.13 | +14.54% | Beat | -7.1% | 12 | 1 up, 1 down | Feb 24, 2026 | $1.14B |
| Sep 30, 2025 | $0.19 | $0.13 | $0.11 - $0.15 | +46.15% | Beat | +46.2% | 11 | 3 up, 1 down | Nov 5, 2025 | $1.14B |
| Jun 30, 2025 | $0.26 | $0.20 | $0.18 - $0.22 | +30.00% | Beat | -13.3% | 10 | 1 up, 1 down | Aug 7, 2025 | $1.24B |
| Mar 31, 2025 | $0.37 | $0.30 | $0.26 - $0.33 | +23.33% | Beat | +8.8% | 10 | 1 up, 4 down | May 7, 2025 | $1.19B |
| Dec 31, 2024 | $0.14 | $0.15 | $0.13 - $0.17 | -5.79% | Miss | +75.0% | 11 | 1 up, 2 down | Feb 25, 2025 | $1.02B |
| Sep 30, 2024 | $0.13 | $0.12 | $0.10 - $0.13 | +8.33% | Beat | -27.8% | 10 | 1 up, 0 down | Nov 7, 2024 | $1.03B |
| Jun 30, 2024 | $0.30 | $0.24 | $0.23 - $0.26 | +25.00% | Beat | +66.7% | 10 | 0 up, 1 down | Aug 8, 2024 | $1.18B |
| Mar 31, 2024 | $0.34 | $0.27 | $0.25 - $0.27 | +25.93% | Beat | -24.4% | 10 | 0 up, 0 down | May 8, 2024 | $1.21B |
| Dec 31, 2023 | $0.08 | $0.11 | $0.08 - $0.13 | -27.27% | Miss | -57.9% | 10 | 0 up, 0 down | Feb 26, 2024 | $1.03B |
| Sep 30, 2023 | $0.18 | $0.12 | $0.09 - $0.15 | +50.00% | Beat | -10.0% | 9 | 0 up, 0 down | Nov 7, 2023 | $1.07B |
| Jun 30, 2023 | $0.18 | $0.05 | $0.03 - $0.06 | +260.00% | Beat | -50.0% | 9 | 0 up, 0 down | Aug 7, 2023 | $1.06B |
| Mar 31, 2023 | $0.45 | $0.29 | $0.25 - $0.32 | +55.17% | Beat | +25.0% | 9 | 4 up, 0 down | May 9, 2023 | $1.26B |
| Dec 31, 2022 | $0.19 | $0.13 | $0.12 - $0.14 | +46.15% | Beat | -9.5% | 10 | 0 up, 0 down | Feb 21, 2023 | $984.00M |
| Sep 30, 2022 | $0.20 | $0.16 | $0.14 - $0.18 | +25.00% | Beat | +5.3% | 10 | 0 up, 0 down | Nov 8, 2022 | $1.03B |
| Jun 30, 2022 | $0.36 | $0.25 | $0.23 - $0.28 | +44.00% | Beat | +28.6% | 10 | 0 up, 1 down | Aug 8, 2022 | $1.18B |
| Mar 31, 2022 | $0.36 | $0.35 | $0.34 - $0.38 | +2.86% | Beat | -2.7% | 9 | 0 up, 2 down | May 9, 2022 | $1.23B |
| Dec 31, 2021 | $0.21 | $0.17 | $0.16 - $0.20 | +23.53% | Beat | +75.0% | 10 | 0 up, 0 down | Feb 24, 2022 | $1.11B |
| Sep 30, 2021 | $0.19 | $0.17 | $0.15 - $0.18 | +11.76% | Beat | +46.2% | 12 | 0 up, 1 down | Nov 5, 2021 | $1.13B |
| Jun 30, 2021 | $0.28 | $0.26 | $0.24 - $0.30 | +7.69% | Beat | +211.1% | 12 | N/A | Aug 9, 2021 | $1.28B |
| Mar 31, 2021 | $0.37 | $0.23 | $0.20 - $0.25 | +60.87% | Beat | +184.6% | 11 | N/A | May 7, 2021 | $1.24B |
| Dec 31, 2020 | $0.12 | $0.09 | $0.08 - $0.10 | +33.33% | Beat | -47.8% | 11 | N/A | Feb 24, 2021 | $1.14B |
| Sep 30, 2020 | $0.13 | $0.12 | $0.06 - $0.19 | +8.33% | Beat | -56.7% | 12 | N/A | Nov 6, 2020 | $890.00M |
| Jun 30, 2020 | $0.09 | $0.07 | -$0.02 - $0.20 | +28.57% | Beat | -67.9% | 12 | N/A | Jul 30, 2020 | $586.00M |
| Mar 31, 2020 | $0.13 | $0.24 | $0.16 - $0.27 | -45.83% | Miss | -48.0% | 11 | N/A | May 7, 2020 | $658.00M |
| Dec 31, 2019 | $0.23 | $0.23 | $0.21 - $0.26 | 0.00% | In line | -20.7% | 12 | N/A | Feb 19, 2020 | $787.00M |
| Sep 30, 2019 | $0.30 | $0.26 | $0.22 - $0.27 | +15.38% | Beat | +3.4% | 11 | N/A | Nov 6, 2019 | $771.30M |
| Jun 30, 2019 | $0.28 | $0.26 | $0.24 - $0.27 | +7.69% | Beat | N/A | 10 | N/A | Aug 13, 2019 | $781.60M |
| Mar 31, 2019 | $0.25 | $0.23 | $0.20 - $0.26 | +8.70% | Beat | N/A | 11 | N/A | May 9, 2019 | $731.10M |
| Dec 31, 2018 | $0.29 | $0.27 | $0.25 - $0.34 | +7.41% | Beat | N/A | 10 | N/A | Feb 6, 2019 | $799.30M |
| Sep 30, 2018 | $0.29 | $0.25 | $0.24 - $0.27 | +16.00% | Beat | N/A | 8 | N/A | Nov 6, 2018 | $761.10M |
| Jun 30, 2018 | -$0.97 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 21, 2018 | $770.20M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.95, within 4 cents of the year before. It was -$0.39 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.95 | N/A |
| Dec 31, 2024 | $0.91 | N/A |
| Dec 31, 2023 | $0.89 | -19.8% |
| Dec 31, 2022 | $1.11 | +5.7% |
| Dec 31, 2021 | $1.05 | +123.4% |
| Dec 31, 2020 | $0.47 | -55.7% |
| Dec 31, 2019 | $1.06 | N/A |
| Dec 31, 2018 | -$0.39 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 10,230 | 16 | |
| 2026Q2 | Jun 30, 2026 | 8,084 | 13 | |
| 2026Q1 | Mar 31, 2026 | 8,041 | 13 | |
| 2025Q4 | Dec 31, 2025 | 9,370 | 12 | |
| 2025Q3 | Sep 30, 2025 | 8,455 | 14 | |
| 2025Q2 | Jun 30, 2025 | 9,308 | 13 | |
| 2025Q1 | Mar 31, 2025 | 9,872 | 12 | |
| 2024Q4 | Dec 31, 2024 | 3,119 | 13 |
2026Q3 Earnings Call
Opening remarks
Tiffany Ann Kanaga Vice President of Investor Relations and ESG Good morning. Thank you for joining us for Elanco Animal Health's third quarter 2026 earnings call. I am Tiffany Ann Kanaga, Vice President of Investor Relations and ESG. Joining me on today's call are Jeffrey N. Simmons, our president and chief executive officer; Robert VanHimbergen, our chief financial officer; and Beth Haney from investor relations. The slides referenced during this call are available on the Investor Relations section of elanco.com. Today's discussion will include forward-looking statements. These statements are based on our current assumptions and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information, see the risk factors discussed in today's earnings press release as well as in our latest Form 10-K and 10-Q filed with the SEC. We do not undertake any duty to update any forward-looking statements. Our remarks today will focus on our non-GAAP financial measures. Reconciliations of these non-GAAP measures are included in the appendix of today's slides and in the earnings press release. References to organic performance represent revenue growth, excluding the impacts from royalty revenue and sales-based milestones that were sold to a third party, foreign exchange rates, and acquisitions and divestitures. After our prepared remarks, we will be happy to take your questions. I will now turn the call over to Jeffrey.
Jeffrey N. Simmons President and CEO Thanks, Tiffany. Good morning, everyone. Elanco delivered an outstanding third quarter, outperforming our commitments and growing revenue 11% on a reported basis, or 9% in organic constant currency. We are growing the right way, with accelerating price up 4% and volume up 5%, reflecting the value created by our basket of innovation and our diverse portfolio. This translated to significant gross margin expansion, up 300 basis points, and greater free cash flow, moving our net leverage ratio under the 3.0x milestone. Growth, innovation, cash. We are consistently executing along these three priorities, powered by our balanced business profile, strategically built to produce results as the industry and competition evolve. And we are just getting started, with significant runway for share gains off a small base in large, growing global markets. As highlighted on Slide 4, Elanco exceeded the high end of guidance for revenue, adjusted EBITDA and adjusted EPS. Growth was led by International Pet Health, up 17%, and U.S. Pet Health, up 13%, with positive contributions from Global Farm Animal. In the third quarter, we saw strong veterinarian and pet owner demand for what we believe is best-in-medicine innovation that we are bringing to the table. Zenrelia once again led total Elanco growth, with Credelio Quattro also a major contributor. Both brands achieved record market share in the U.S. in September.
Frequently Asked Questions About ELAN
When is Elanco Animal Health's next earnings date?
Elanco Animal Health's next earnings report is expected for Feb 22, 2027.
Did ELAN beat earnings estimates last quarter?
Yes. Elanco Animal Health reported EPS of $0.27 for the quarter ended Sep 30, 2026, above the $0.20 estimate, a 35.00% surprise.
What EPS do analysts expect from ELAN next quarter?
The consensus EPS estimate for Elanco Animal Health for the quarter ending Dec 31, 2026 is $0.18 from 15 analysts, with estimates from $0.14 to $0.20.
How often does ELAN beat earnings estimates?
Elanco Animal Health beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +23.35%.
ELAN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors